Loading...
•
Jun 30, 2024
HCA Q2 2024 Earnings Report
HCA Healthcare's financial performance was positive, demonstrating strong demand and effective execution of strategic plans.
Key Takeaways
HCA Healthcare reported strong second-quarter results with revenues of $17.492 billion and net income of $1.461 billion, or $5.53 per diluted share. The company's performance reflected strong demand for its services and effective execution of its strategic plan. HCA Healthcare also raised its 2024 guidance.
Revenues totaled $17.492 billion.
Net income attributable to HCA Healthcare, Inc. totaled $1.461 billion, or $5.53 per diluted share.
Adjusted EBITDA totaled $3.550 billion.
Cash flows from operating activities totaled $1.971 billion.
HCA
HCA
Forward Guidance
HCA Healthcare revised its 2024 estimated guidance ranges issued on January 30, 2024.
Positive Outlook
- Revenues: $69.750 to $71.750 billion
- Net Income Attributable to HCA Healthcare, Inc.: $5.675 to $5.975 billion
- Adjusted EBITDA: $13.750 to $14.250 billion
- EPS (diluted): $21.60 to $22.80 per diluted share
- Capital expenditures for 2024, excluding acquisitions, are estimated to be in the range of $5.1 to $5.3 billion.
Challenges Ahead
- The Company’s revised 2024 guidance contains a number of assumptions, including, among others, the Company’s current expectations regarding patient volumes and payor mix as well as general economic conditions, including inflation.
- Excludes the impact of items such as, but not limited to, gains or losses on sales of facilities, losses on retirement of debt, legal claims costs and impairment of long-lived assets.
- The Company’s guidance is based on current plans and expectations and is subject to a number of known and unknown uncertainties and risks.
- Changes in revenues due to declining patient volumes
- Potential increased expenses related to labor, supply chain or other expenditures